

**Amendments To The Claims**

The listing of claims will replace all prior versions, and listings, of the claims in the application.

**Listing Of Claims:**

Claim 1 (Currently Amended) A method of treating a critically ill patient [and/or] or a critically ill polyneuropathy (CIPNP)-patient [and/or a potential CIPNP-patient] , said method comprising administering a blood glucose regulator to [a] said critically ill patient [,] or said [a] CIPNP-patient[, and/or a potential CIPNP-patient] in an amount effective to maintain blood glucose levels in said patient within a range of from about 60 mg/dL to about 130 mg/dL.

Claim 4. (Currently Amended) A method of treating a patient suffering from [or at risk of] CIPNP[, multiple organ failure, need for mechanical ventilatory support, renal replacement therapy, disturbed kidney function parameters, hyperbilirubinemia, blood stream infections; inflammations and/or inflammatory responses, need for antibiotics, red cell transfusion, stress induced hyperglycaemia, risk of repetitive positive EMGs, cholestasis, or a condition of insulin resistance leading to hyperinsulinemia in combination with hyperglycaemia], said method comprising treating [such a] said patient with a blood glucose regulator in an amount effective to treat said CIPNP.

5. (Currently Amended) The method of claim [5] 4, wherein the blood glucose regulator is insulin, active insulin derivatives[,] or insulin analogues[, compounds that stimulate signal transduction mediated by an insulin receptor type tyrosine kinase in a cell, certain protein-tyrosine phosphatases (PTP's), other type II antidiabetica, and other biologically active substances having insulin releasing action, preferably insulin].

6. (Currently Amended) The method of claim [5] 4, wherein the blood glucose regulator is a blood glucose regulator which is not to be administered orally.

7. (Currently Amended) The method of claim [5] 4, wherein the blood glucose regulator is administered in an amount effective to maintain blood glucose levels in said patient within a range [between 60- 130 mg/dL] of from about 60 mg/dL to about 130 mg/dL.

8. (Currently Amended) The method of claim 7, wherein [the] said blood glucose [level is] levels are maintained within a range [between 80-110 mg/dL] of from about 80 mg/dL to about 110 mg/dL.

9. (Currently Amended) The method of claim [5] 4, wherein [the] said blood glucose [level is] levels are maintained for 8 hours or more.

10. (Currently Amended) The method of claim 9, wherein said blood glucose [level is] levels are maintained for 24 hours or more.

11. (Currently Amended) The method of claim 10, wherein said blood glucose [level is] levels are maintained for 4 days or more.

12. (Currently Amended) The method of claim [5] 4, wherein the patient is a mammal.

13. (Previously Presented) The method of claim 12, wherein the patient is a human.

14. (Previously Presented) The method of claim 13, wherein the patient is non-diabetic.

Claims 15-21 (Cancelled)

Claim 22 (New) The method of claim 1, wherein said blood glucose regulator is administered to said critically ill patient or to said CIPNP patient in an amount effective to maintain blood glucose levels in said patient within a range from about 70 mg/dL to about 120 mg/dL.

Claim 23 (New) The method of claim 1, wherein said blood glucose regulator is administered to said critically ill patient or to said CIPNP patient in an amount effective to maintain blood glucose levels in said patient within a range from about 80 mg/dL to about 110 mg/dL.

Claim 24 (New) The method of claim 1, wherein said blood glucose levels are maintained within a range from about 60 mg/dL to about 130 mg/dL for 8 hours or more.

Express Mail Label No. EV 409530457 US  
Attorney Docket No. 6296.204-US  
Serial No. 09/853,193

Claim 25 (New) The method of claim 1, wherein said blood glucose levels are maintained within a range from about 60 mg/dL to about 130 mg/dL for 24 hours or more.

Claim 26 (New) The method of claim 1, wherein said blood glucose levels are maintained within a range from about 60 mg/dL to about 130 mg/dL for 4 days or more.

Claim 27 (New) The method of claim 1, wherein the patient is a mammal.

Claim 28 (New) The method of claim 27, wherein the patient is a human.

Claim 29 (New) The method of claim 28, wherein the patient is non-diabetic.

Claim 30 (New) The method of claim 1, wherein the blood glucose regulator is a blood glucose regulator which is not to be administered orally.

Claim 31 (New) The method of claim 1, wherein the blood glucose regulator is insulin, active insulin derivatives or insulin analogues.